ANN ARBOR, Mich. – April 29, 2013 – Lycera Corp., a biopharmaceutical company pioneering the development of breakthrough oral medicines to treat autoimmune diseases, today announced the appointment of Bruce A. Goldsmith, Ph.D., as chief business officer. In this new position, Dr. Goldsmith will work as part of the executive team to implement the company’s corporate strategy and will lead the company’s business development efforts.
“We are pleased to welcome Bruce to Lycera’s management team. He brings a proven track record of driving corporate and product strategy, leading business development efforts and creating valuable external partnerships,” said Kathleen M. Metters, Ph.D., Lycera president and chief executive officer. “As Lycera transitions into a clinical stage company, we continue to expand our pipeline of novel oral therapies for autoimmune disorders. Bruce will be key to our efforts to evaluate and implement a strategic blend of proprietary and partnered programs.”
Dr. Goldsmith has more than 15 years of experience in the pharmaceutical and biotechnology industries. Most recently, he served as senior vice president corporate development at Allos Therapeutics, where he helped shape and manage corporate strategy and planning, financing transactions, business development and investor relations. While at Allos, Dr. Goldsmith led the successful sale of the company and, previously, executed a global collaboration for the co-development and commercialization of the company’s lead oncology asset outside of North America. Prior to joining Allos, Dr. Goldsmith served as vice president, strategic marketing at GPC Biotech. Previously, he held various strategic marketing and business development positions with the Johnson & Johnson family of companies, including roles as group product director, virology and global marketing leader, oncology. Dr. Goldsmith holds an M.B.A. from Columbia Business School, a Ph.D. in neuroscience from the University of Pennsylvania and a B.A. in biology from Colgate University.
“This is an exciting time for Lycera as the company continues to advance its innovative pipeline of product candidates for autoimmune diseases to address areas of incredible unmet medical need,” said Dr. Goldsmith. “I am looking forward to collaborating with Lycera’s leading scientists and the company’s existing and future external partners to help realize the full potential of our next-generation autoimmune therapies.”
Lycera Corp. is focused on the discovery and development of selective, oral, small-molecule immune-modulators for the treatment of patients with autoimmune diseases such as rheumatoid arthritis, psoriasis and inflammatory bowel disease. Lycera is developing drug candidates for novel therapeutic targets that have the potential for first-in-class oral efficacy without the adverse effects of current standard-of-care antiproliferative and immunosuppressive agents. Lycera is focused on the emerging areas of cellular bioenergetics and immune-metabolism to selectively target and silence pathologically activated cells. Lycera has significant research collaborations with Merck to discover, develop and commercialize multiple small-molecule therapies for autoimmune disorders. Lycera’s leadership team and advisors represent the core thought leaders in immunology, inflammation, medicinal chemistry and relevant biology and are responsible for key advances and discoveries in these fields.